For the n = 14 PIK3CA mutation-positive patients (26.4%) included in the current study, a significantly higher PIK3CA VAF was also detected in the DCIS component (52.3%) when compared with the synchronous IBC component (37.2%) (p = 0.027). The gene discussed is PIK3CA; the disease is ductal breast carcinoma in situ.